Discover how Chroma is expanding our impact.

Boston, MA, March 1, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion of a $135 million Series B financing led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management. The financing will support advancement of Chroma’s therapeutic programs toward the clinic, and continued investment in the…

Cambridge, MA, October 4, 2022 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the addition of Jeff Marrazzo, co-founder and former founding CEO of Spark Therapeutics, to its Board of Directors. “Jeff’s leadership at Spark yielded the first-ever approved gene therapy, and we are thrilled to bring his expertise to the Chroma Board,” said Catherine Stehman-Breen, M.D., CEO of Chroma. “He is a proven company builder who has successfully led the advancement of novel genomic medicines to patients. His unique perspective as a gene therapy pioneer will be instrumental as we reimagine…

Cambridge, MA, September 20, 2022 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB) comprising renowned leaders in epigenetics, cell and gene therapy, and synthetic biology: Bradley Bernstein, M.D., Ph.D., Paula Cannon, Ph.D., Howard Chang, M.D., Ph.D., and Ahmad (Mo) Khalil, Ph.D. The SAB members will provide key input to Chroma as the company advances its programs addressing a wide range of diseases. “Each of these distinguished experts will be instrumental as we unlock the potential of epigenetic editing therapeutics,” said Catherine Stehman-Breen, M.D., Chief…

Cambridge, MA, May 24, 2022 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering epigenetic editing therapeutics, today announced the appointment of George Golumbeski, Ph.D., former Executive Vice President of Business Development at Celgene, as an Independent Director and John Maraganore, Ph.D., former CEO of Alnylam, as a Strategic Advisor. “We are thrilled to welcome George and John to the Chroma team. They are both remarkable pioneers in building leading biotechnology companies that have brought important innovative treatments to patients,” said Catherine Stehman-Breen, M.D., Chief Executive Officer of Chroma. “Their deep experience will be invaluable to Chroma and the…